Zydus Lifesciences PE ratio history and valuation
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.50.
29 Oct: open ₹1,175.50, high ₹1,187.80, low ₹1,170.50
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,18,144 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.18
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 23.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.36
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,55,85055.6% delivered
Zydus Lifesciences' P/E without one-off items, price to book, price to sales, EV to EBITDA, dividend yield and earnings yield on 29 Oct 2026, each against its own history of up to 10 years. The P/E is the market cap over the profit of the twelve months to Jun 2026.
Zydus Lifesciences PE ratio and valuation against its own history
- P/E without one-off itemsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth.23.41today
1 year
Median 19.28Today is at or above 98% of the 247 days
3 years
Median 21.71Today is at or above 74% of the 744 days
5 years
Median 20.88Today is at or above 79% of the 1,239 days
10 years
Median 22.10Today is at or above 60% of the 2,479 days
- Price to book4.36today
1 year
Median 3.77Today is at or above 97% of the 247 days
3 years
Median 4.15Today is at or above 65% of the 744 days
5 years
Median 3.72Today is at or above 79% of the 1,239 days
10 years, since Nov 2018
Median 3.73Today is at or above 82% of the 1,979 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.4.13today
1 year
Median 3.85Today is at or above 89% of the 247 days
3 years
Median 4.15Today is at or above 48% of the 744 days
5 years
Median 3.75Today is at or above 69% of the 1,239 days
10 years
Median 3.47Today is at or above 72% of the 2,479 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.15.45today
1 year
Median 13.37Today is at or above 98% of the 247 days
3 years
Median 14.40Today is at or above 70% of the 744 days
5 years
Median 14.26Today is at or above 76% of the 1,239 days
10 years, since Nov 2018
Median 14.29Today is at or above 70% of the 1,979 days
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.08%today
1 year
Median 1.16%Today is at or above 3% of the 247 days
3 years
Median 0.60%Today is at or above 1% of the 744 days
5 years
Median 0.64%Today is at or above 1% of the 1,239 days
10 years
Median 0.76%Today is at or above 8% of the 2,479 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.3.82%today
1 year
Median 5.16%Today is at or above 3% of the 247 days
3 years
Median 4.43%Today is at or above 22% of the 744 days
5 years
Median 4.52%Today is at or above 18% of the 1,239 days
10 years
Median 4.32%Today is at or above 32% of the 2,479 days
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to earnings =Market cap÷Net profit, last twelve monthsNet profit, last twelve months. Net profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹4,513 Cr
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹27,111 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹28,592 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹11,770 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹1,417 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹8,316 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.99,75,03,832at 30 Sep 2026
Consolidated accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Zydus Lifesciences financials ›
Zydus Lifesciences valuation at each year end
On the last trading day of each March, the month the company's year ends.Zydus Lifesciences dividend history
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 45,249 | 38,682 | 35,529 | 27,360 | 45,137 | 35,677 | 49,755 | 1,01,964 | 89,193 | 87,663 |
| Price to earnings | 33.2 | 24.6 | 17.9 | 22.0 | 24.4 | 7.5 | 24.1 | 34.3 | 19.7 | 17.8 |
| Price to book | No balance sheet | No balance sheet | 4.0 | 2.7 | 3.8 | 2.2 | 3.0 | 5.4 | 4.1 | 3.5 |
| Price to sales | 4.8 | 3.4 | 2.8 | 1.9 | 3.0 | 2.3 | 3.0 | 5.4 | 4.0 | 3.4 |
| EV to EBITDA | No balance sheet | No balance sheet | 13.1 | 12.3 | 14.9 | 11.7 | 15.5 | 20.2 | 13.4 | 11.7 |
| Dividend yield | 0.72% | 0.00% | 1.01% | 2.62% | 0.00% | 1.00% | 0.51% | 0.60% | 0.34% | 1.26% |
| Earnings yield | 3.0% | 4.1% | 5.6% | 4.5% | 4.1% | 13.4% | 4.1% | 2.9% | 5.1% | 5.6% |
Zydus Lifesciences market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Earnings per share, book value and enterprise value
From the close on 29 Oct 2026, with the last twelve months' results.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹1,28,497 Cr
- Earnings per shareEarnings per share, trailing. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) divided by the number of shares in issue.
- ₹45.24
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹271.79
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- ₹1.00
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹29,524 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Zydus Lifesciences is 5th among them by market cap. Each median leaves out Zydus Lifesciences itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.4Across 157 other companies
- Listed companies with this P/E or lowerP/E among all listed companies. The share of the 3,446 listed companies with a trailing P/E on 29 Oct 2026 whose P/E is at or below Zydus Lifesciences'.
- 59%Of 3,446 companies with a P/E
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 3.0Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.1Across 143 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.48%Across 88 other companies
| Company | |||||
|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,22,523 | 34.93 | 5.06 | 23.3 | 0.91% |
 Divi's LaboratoriesDIVISLAB | 2,56,549 | 87.71 | 15.31 | 63.8 | 0.31% |
 Torrent PharmaceuticalsTORNTPHARM | 1,74,208 | 82.02 | 9.48 | 32.4 | 0.83% |
 Laurus LabsLAURUSLABS | 1,21,246 | 90.49 | 20.01 | 52.0 | 0.09% |
| Zydus LifesciencesZYDUSLIFE | 1,18,144 | 26.18 | 4.36 | 15.5 | 0.08% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,12,264 | 40.10 | 2.89 | 23.6 | 0.59% |
 CiplaCIPLA | 1,09,709 | 37.87 | 3.10 | 22.5 | 0.96% |
 Mankind PharmaMANKIND | 1,01,993 | 45.36 | 5.80 | 26.1 | 0.00% |
 Aurobindo PharmaAUROPHARMA | 95,507 | 25.73 | 2.52 | 13.2 | 0.00% |
Stakes in other listed companies
At market prices on 29 Oct 2026. Not published: the stakes are worth 7.4% of the company's own market cap, under the 25% this figure is about.
- Its own market capIts own market cap. Closing price × shares in issue.
- ₹1,18,144 Cr
- Its stakes, at marketIts stakes, at market. Each stake's per cent × that company's market cap, added up.
- ₹8,786 Cr
- Zydus Wellness57.59%₹8,786 Cr